“The remaining proceeds from our recent financing further strengthened our balance sheet and our ability to execute the long-range plan we presented at our investor day held last month in New York ...

Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGSNet product sales of FILSPARI ...

Weave (NYSE: WEAV), a leading all-in-one customer experience and payments software platform for small and medium-sized ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ...

February 20, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a trailblazer in healthcare and supplementation, proudly announces ...

By leveraging CytoImmune's Bioreactor technologies, Hemostemix secures an allogenic supply of stem cells that strategically complements its autologous offering. This creates a "stem cell fence" -a ...

Q4 2024 Earnings Call Transcript February 19, 2025 OneSpaWorld Holdings Limited misses on earnings expectations. Reported EPS ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales Company reaffirms combined peak sales of IB ...

Declarations of love, snoring, exercising and other boundary violations can really derail a therapeutic relationship.

Most of us are exposed to a high volume of falsehoods, day in and day out. What are the effects on our decision making?